PT - JOURNAL ARTICLE AU - Kumar AK Hemanth AU - PL Natarajan AU - T Kannan AU - R Sridhar AU - S Kumar AU - Kumar V Vinod AU - NS Gomathi AU - T Bharathiraja AU - V Sudha AU - S Balaji AU - S Rameshkumar AU - Dina Nair AU - SP Tripathy AU - R Geetha TI - Pharmacokinetics of anti-tuberculosis drugs in multidrug resistant tuberculosis patients in India AID - 10.1101/2020.05.26.20111534 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.26.20111534 4099 - http://medrxiv.org/content/early/2020/05/27/2020.05.26.20111534.short 4100 - http://medrxiv.org/content/early/2020/05/27/2020.05.26.20111534.full AB - Programmatic Management of multidrug resistant tuberculosis (MDR TB) services were introduced in the Indian TB control programme in 2007. A pharmacokinetic (PK) study of drugs used to treat MDR TB, namely levofloxacin (LFX), ethionamide (ETH), cycloserine (CS), pyrazinamide (PZA), moxifloxacin (MFX) and isoniazid (INH) was undertaken in adult MDR TB patients treated according to the prevailing guidelines in India. Factors influencing drug PK and end-of-intensive phase (IP) status were also determined. We recruited 350 MDR TB patients receiving anti-TB treatment (ATT) in the Indian Government programme in south India. At steady state, serial blood samples were collected, after supervised drug administration. Status at end of IP was noted from the programme records. Of the 303 patients for whom end-of-IP status was known, 214 were culture negative (responders), while 45 patients were either culture positive or required change of regimen or had died before completion of IP (non-responders). The median Cmax (2.0 vs 2.9μg/ml; p = 0.005) and AUC0-12 (12.2 vs 17.0μg/ml.h; p = 0.002) of ETH were significantly lower in non-responders than responders at IP. In multivariate logistic regression analysis, after excluding defaulters and adjusting for confounders, AUC0-12 of ETH significantly influenced end-of-IP status (aOR - 1.065; 95% CI: 1.001 - 1.134; p = 0.047). Drug doses used currently in the programme produced optimal drug concentrations in majority of patients. ETH played a major role in the MDR TB combination regimen and was a key determinant of end-of-IP status.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo extra mural funding was received to conduct this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:National Institute for Research in Tuberculosis - Institutional Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll study data is available at the institute where the research study was undertaken (National Institute for Research in Tuberculosis).